Search details
1.
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Lancet
; 401(10394): 2124-2137, 2023 06 24.
Article
in English
| MEDLINE | ID: mdl-37302395
2.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 24(12): 1359-1374, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37926100
3.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Breast Cancer Res
; 25(1): 39, 2023 04 12.
Article
in English
| MEDLINE | ID: mdl-37046348
4.
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
Breast Cancer Res Treat
; 197(2): 405-416, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36396774
5.
Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting.
BMC Med Ethics
; 24(1): 105, 2023 11 28.
Article
in English
| MEDLINE | ID: mdl-38017503
6.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Article
in English
| MEDLINE | ID: mdl-36096872
7.
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
JAMA
; 327(20): 1963-1973, 2022 05 24.
Article
in English
| MEDLINE | ID: mdl-35608580
8.
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Lancet
; 395(10237): 1613-1626, 2020 05 23.
Article
in English
| MEDLINE | ID: mdl-32580883
9.
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Int J Gynecol Cancer
; 31(11): 1471-1475, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34518240
10.
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Lancet Oncol
; 21(11): 1443-1454, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33152284
11.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32919527
12.
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
Lancet
; 403(10438): 1752, 2024 May 04.
Article
in English
| MEDLINE | ID: mdl-38704171
13.
The Lancet Breast Cancer Commission.
Lancet
; 403(10439): 1895-1950, 2024 May 11.
Article
in English
| MEDLINE | ID: mdl-38636533
14.
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Lancet Oncol
; 20(7): 1023-1034, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31160249
15.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Breast Cancer Res
; 22(1): 2, 2019 12 31.
Article
in English
| MEDLINE | ID: mdl-31892336
16.
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Breast Cancer Res Treat
; 175(1): 149-163, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30680659
17.
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet
; 390(10099): 1048-1060, 2017 Sep 09.
Article
in English
| MEDLINE | ID: mdl-28779963
18.
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
Breast Cancer Res Treat
; 170(3): 573-581, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29700676
19.
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Breast Cancer Res Treat
; 171(1): 65-74, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29766362
20.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28600210